Market Overview

UPDATE: Bank of America Initiates Akorn at Buy on Product, Revenue Mix

Share:
Related AKRX
Top 4 NASDAQ Stocks In The Drugs-Generic Industry With The Highest EPS Growth Forecast For Next 5 Years
Analyst Knocks High-Profile Biotech Merger Battle; Opportunities Elsewhere

Bank of America initiated coverage on Akorn (NASDAQ: AKRX) with a Buy rating and a $18 price objective.

Bank of America commented, "We like AKRX's mix of niche pharma products in generic injectables and ophthalmology. We also like AKRX's diverse revenue base (generic/brand, Rx/OTC), low product concentration risk (top product contributes ~13% of revenues, vs. ~36% for HITK, IPXL), and targeted ex-US operations (sales and manufacturing), which set AKRX apart vs. its small generic peers. As such, we believe the recent pullback in the shares has created an attractive entry point for investors. While our thesis is based on AKRX as an independent entity, we see the company as an attractive asset in a consolidating generic pharma environment."

Akorn closed at $12.04 on Tuesday.

Latest Ratings for AKRX

DateFirmActionFromTo
Jun 2015Raymond JamesInitiates Coverage onOutperform
Apr 2015Piper JaffrayDowngradesOverweightNeutral
Apr 2015JP MorganInitiates Coverage onOverweight

View More Analyst Ratings for AKRX
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Initiation Pre-Market Outlook Analyst Ratings

 

Related Articles (AKRX)

Around the Web, We're Loving...

Get Benzinga's Newsletters